General Atlantic Portfolio Concentration Analysis as of June 30, 2026

As of June 30, 2026, General Atlantic, a prominent investment firm, holds a substantial portfolio valued at approximately $2.1 billion.

The fund's largest position is in DLOCAL (DLO), accounting for 20.86% of its holdings. This significant stake alone represents a considerable portion of the total portfolio value and underscores the level of concentration present, as detailed in their top holdings data.

Following closely are shares in CHIME (CHYM) at 14.98%, XP, INC (XP) at 11.50%, and ALKAMI (ALKT) at 12.08%. These four stocks combined represent a major portion of the portfolio, highlighting that General Atlantic's investment strategy relies heavily on these key positions.

Several holdings show notable changes from the previous period:

• DLOCAL: No change in shares, maintaining its position as a core holding.
• XP, INC: Shares remained unchanged, keeping it steady at 11.50% allocation.
• CHIME: No change in shares, holding steady at its weight.
• ALKAMI: Showed a significant increase of 26.35% in shares during the period.

Examining sector allocation reveals that most of General Atlantic's portfolio falls into the 'Unknown' category, representing 76.71%. This lack of clear sector breakdown can be challenging to analyze further without more information on these specific holdings.

The known sectors include Technology with a total value allocation of $351 million (ALKT is part of this), Healthcare encompassing several smaller positions like NURIX THERAPEUTICS and REVOLUTION MEDICINES, and Consumer Defensive represented by GROVE COLLABORATIVE. The Technology sector specifically accounts for 16.53% of the portfolio value.

While General Atlantic holds a diverse range of companies across various industries (as evidenced by holdings like RISKIFIED and PHARVARIS), their reliance on just four major positions totaling over $1.4 billion in value indicates a concentrated approach to certain opportunities within their investment mandate.